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Summary. Background/objectives: The traditional view that
patients with hemophilia are protected against cardiovascular
disease is under debate. The aim of the present study was to
evaluate the presence and extent of atherosclerosis by coronary
artery calcification score (CACS) and carotid intima media
thickness (IMT) in patients with hemophilia, and to evaluate
their cardiovascular risk profile. Methods: Sixty-nine patients
(51 with hemophilia A; 18 with hemophilia B) were studied
[median age: 52 years (interquartile range [IQR] 43–64)].
Cardiovascular risk factors and prior major adverse cardiovas-
cular events (MACEs) were recorded. CACS was derived from
electron-beam or dual-source computed tomography, and
carotid IMT was assessed by ultrasound measurements and
compared with age-specific reference values. Results: The
median CACS in all patients was 35 (IQR 0–110) and the
geometric mean IMT was 0.80 mm (95% confidence interval
[CI] 0.76–0.84); neither was different from the reference values.
Patients with a previous MACE (n = 9) had significantly
higher CACS and IMT than patients without a previous
MACE:CACSmedian 1013 (IQR 530–1306) vs. 0 (IQR 0–67),
and IMT geometric mean 1.09 mm (95% CI 0.95–1.26) vs.
0.76 mm (95% CI 0.73–0.79), both P < 0.001. A higher
calculated 10-year cardiovascular risk was related to higher
IMT and CACS. Conclusion: Patients with hemophilia are
not protected against the development of atherosclerosis as
measured by CACS and IMT. The extent of atherosclerosis is
related to the traditional cardiovascular risk factors. This
suggests that traditional cardiovascular risk factors should be
monitored and treated in patients with hemophilia.
Keywords: atherosclerosis, cardiovascular risk, coronary artery
calcification score, hemophilia, intima–media thickness.
Introduction
The traditional view that patients with hemophilia are
protected against cardiovascular disease is based on several
European and US studies that found lower mortality rates for
ischemic heart disease in persons with hemophilia than in the
general population, carried out in the period between 1968 and
1993 [1–3]. It was suggested that the hypocoagulable state and a
lower prevalence of cardiovascular risk factors could account
for this. However, recent reports challenge this view. The
presence of coronary artery disease and the lifetime prevalence
of cardiovascular events in patients with hemophilia were
found to be similar to those in the general population [4–6].
Furthermore, in patients with hemophilia and cardiovascular
disease, the presence of coronary disease and cardiovascular
morbidity and mortality were associated with the same
traditional risk factors as in the general population. Cardio-
vascular disease in patients with hemophilia has attracted more
interest in recent years, because decreased mortality from
bleedings and viral infections has resulted in a longer life-
expectancy and consequently longer exposure to cardiovascu-
lar risk factors [7–9].
The sequence of events from the earliest atherosclerotic
changes in the arterial wall to a clinical cardiovascular event is a
gradual process, starting with a fatty streak in the vessel wall,
followed by inflammation, calcification, plaque rupture, and
thrombosis [10]. Consequently, a possible lower prevalence of
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cardiovascular events in hemophilia patients could result from
an alteration of any part of this sequence. Theoretically,
diminished development of atherosclerosis, diminished plaque
vulnerability and a lower tendency to coagulate could
contribute to a decreased risk of a cardiovascular event in a
patient with hemophilia. The present study focused on the
presence and degree of atherosclerosis in this process.
Earlier studies on atherosclerosis using intima–media thick-
ness (IMT) measurements of carotid and femoral arteries in
patients with coagulopathy gave discordant results. A study of
76 patientswith hemophilia or vonWillebrands disease showed
no clinically relevant differences in IMT between patients and
healthy controls [11]. A second study that could not find a
difference in IMT did not report the age of the control group.
This is unfortunate, as age is still the most important determi-
nant of IMT [12]. Two studies in 76 and 40 patients with
hemophilia A, respectively, reported fewer carotid plaques, a
smaller degree of carotid stenosis, and a lower number of
plaques in the aorta and leg arteries [13,14]. Also, a case–control
study found a significantly lower IMT in 50 patients with
hemophilia than in age-matched and sex-matched controls,
whereas their cardiovascular risk factors were comparable [15].
The coronary artery calcification score (CACS) is derived
from new-generation computed tomography (CT) scans of the
heart, and can be used to detect and quantify subclinical
atherosclerosis. Like IMT, CACS can identify atherosclerosis
even at a subclinical level. Furthermore, CACS is currently the
only non-invasive measurement of atherosclerosis at the heart.
Both methods are highly predictive for cardiovascular events,
even in the general population and patients at low to
intermediate cardiovascular risk [16–20].
There are no reports on CACS as measure of subclinical
atherosclerosis in patients with hemophilia. The aim of our
study was to evaluate the presence and extent of atherosclerotic
lesions by CACS and IMT, and to assess the cardiovascular
risk profile in patients with hemophilia.
Materials and methods
Study design
Across-sectional studywas performed in a cohort of unselected
patients with hemophilia A or B registered with the Hemo-
philia Treatment Center of the University Medical Center
Groningen from 2006 to 2009.
Participants
Eligible patients were male, at least 30 years of age, and had
hemophilia A or B. Patients were invited to visit the outpatient
clinic or were included during their regular visit.
Cardiovascular risk factors
All traditional cardiovascular risk factors were assessed.
Hypertension was defined as either a systolic blood pressure
of> 140 mmHg or a diastolic blood pressure of> 90mmHg,
or current use of blood pressure-lowering medication [21].
Overweight was defined as a bodymass index of> 25 kg m)2.
Smoking status (current, past, or never), family history of
premature cardiovascular disease (cardiovascular event in first-
degree relatives, male aged < 55 years and female aged < 65
years) and use of blood glucose-lowering drugs were obtained
with a questionnaire. The 10-year mortality risk for cardiovas-
cular disease was calculated with the Systemic Coronary Risk
Evaluation (SCORE) adjusted for the Dutch population,
which is used for risk assessment in a primary prevention
setting [22]. The UK Prospective Diabetes Study risk engine
was used for patients with diabetes mellitus [23]. All patients
with a prior major adverse cardiovascular event (MACE) were
classified as having a high (> 10%) 10-year risk for cardio-
vascular mortality. MACE was defined as acute coronary
syndrome (ACS), percutaneous coronary intervention (PCI),
coronary artery bypass graft (CABG), peripheral arterial
occlusive disease (PAOD), abdominal aortic aneurysm
(AAA), peripheral revascularization interventions, stroke,
and carotid revascularization.
Laboratory testing
Total cholesterol, triglycerides, LDL cholesterol and HDL
cholesterol were assessed in a fasting state (Modular; Roche
Diagnostics, Almere, The Netherlands).
CT for coronary calcium scoring
Scanning was performed on an electron-beam CT scanner
(C-150 EBT; GE-Imatron, South San Francisco, CA, USA)
for the first 44 patients, or on a dual-source CT scanner
(SOMATOM Definition; Siemens Healthcare, Forchheim,
Germany) for the remainder of the patients. Before the subjects
were scanned, they practiced breath-holding. The scan range
was from the level of the root of the aorta through the heart.
Images were acquired at 80% of the cardiac cycle (at 70% for
dual-source CT), with electrocardiogram triggering, during a
single breath-hold. Quantification of coronary calcification was
performed with dedicated software (in the case of electron-
beam CT, AccuImage Diagnostics Corporation, South San
Francisco, CA, USA; in the case of dual-source CT, SYNGO,
Siemens Healthcare). Trained scan readers were blinded to the
clinical data of the participants. A calcification was defined as a
minimum of two adjacent pixels (area = 0.52 mm2) with a
density over 130 Hounsfield Units (HU), based on the method
in a population-based study [20]. A calcium score for the
coronary arterial tree was calculated according to Agatstons
method [24]. In this scoring method, the area (in square
millimeters) of individual calcified lesions is multiplied by a
factor based on the maximum density of the lesion. This factor
ranges from 1 to 4 in the following manner: 1, 130–199 HU; 2,
200–299 HU; 3, 300–399 HU; and 4, ‡ 400 HU. The total
calcium score was obtained by adding up the scores for all
individual lesions. Electron-beam CT was replaced by
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dual-source CT during the study period. The resulting CACS
was comparable for the two scanning methods, as shown in a
previous validation study [25]. CACS was compared with the
reference values of the white ethnic subgroup (n = 2619) from
the Multi-Ethnic Study of Atherosclerosis (MESA) cohort of
patients free of cardiovascular disease [26]. In this study, each
standard deviation (SD) increase in CACS was related to a 2.1-
fold increased risk for future cardiovascular disease and a 2.5-
fold increased risk for coronary heart disease in the next
5.3 years, corrected for traditional cardiovascular risk factors
[26]. CACS was considered to be increased if the value was
higher than the age-specific and sex-specific geometric
mean + 1 SD according to the reference values. CACS was
also classified into four different categories – 0–100, 101–400,
401–1000, and above 1000 – according to the categorization in
the population-based Rotterdam Study [20]. These categories
of increasing calcium scores are associated with increasing risk
of cardiovascular events [20,27,28].
Carotid ultrasound imaging
We measured the carotid IMT as described previously [29].
High-resolution B-mode ultrasonography (Acuson 128XP10;
Acuson Corporation, Mountainview, CA, USA) with a 7-
MHz linear array transducer was used with the patient in a
supine position. For both carotid arteries, the far wall segments
of the common carotid artery and internal carotid artery were
imaged from a fixed lateral transducer position. The sonogra-
phers were unaware of the risk factors of the studied persons.
The measurements were analyzed online. An IMT that was
thicker than the age-specific 80th percentile was considered to
be abnormal [30]. As IMT measurement is not as well
standardized worldwide as CACS, and regional differences
have been reported [31], local reference values were used from
healthy individuals.
Statistical analysis
As the IMT data are normalized by log transformation, the
geometric means and 95% confidence intervals (CIs)
(± 2 · standard error of the mean) are presented. CACS data
were processed after natural log of (CACS + 1) as in the
MESA study [26]. Data analyses were performed by using SPSS
version 16 (SPSS, Chicago, IL, USA). The chi-squared test
(Fishers exact test) was used for categorical data, the Mann–
Whitney test for non-parametric data, and Students t-test for
normally distributed data. For comparisons across multiple
groups, ANOVA and the Kruskal–Wallis test were used where
appropriate.
Results
Participants and risk factors for cardiovascular disease
Patient characteristics are described in Table 1. One hundred
and thirty-six male hemophilic patients were eligible, 69 of
whom agreed to participate (51%). Forty-two did not respond
to the invitation. Thirteen patients were irretrievable. Twelve
patients declined to participate. Participants and non-partici-
pants did not differ in type or severity of hemophilia. Of the
participants, 51 (74%) had hemophilia A and 18 (26%) had
hemophilia B. Hemophilia was severe (factor VIII or
FIX < 1%) in 27 patients, moderate (FVIII or FIX 1–5%)
in eight, and mild (FVIII or FIX > 5%) in 34. Twenty-four
were receiving prophylactic treatment. The median age was
52 years (interquartile range [IQR] 43–64). The cardiovascu-
lar risk profile is shown for the complete cohort and for the
patients with and without a previous MACE (Table 1). As
stated earlier, patients with a previous MACE are, by
definition, at high cardiovascular risk. In contrast, the
patients without a previous MACE had a low estimated
10-year risk for cardiovascular death: medians of 7% for the
patients with diabetes and of 2% for the patients without
diabetes.
Previous cardiovascular events
Nine patients (13%) had already experienced a MACE,
including two with ACS and one with AAA. One was
diagnosed with PAOD and underwent CABG surgery. Two
had undergone CABG, one PCI, one PCI and CABG, and one
PCI and left-sided and right-sided carotid desobstruction. Both
ACS events occurred during clotting factor replacement for
elective surgery. Patients with a previous MACE were older,
and more often had hypertension, and were treated with blood
pressure-lowering and cholesterol-lowering drugs (Table 1).
Coronary calcification
Figure 1A shows the CACS distribution and the age-depen-
dent reference values. In three patients, CACS was not
performed; two of them had a history of coronary disease,
and one had peripheral occlusive arterial disease. CACS in all
hemophilic patients (median 35, IQR 0–110) did not differ
from the reference values. Nine (14%) patients had an
increased CACS. Patients without a previous MACE had a
median CACS of 0 (IQR 0–67), with the score being < 100 in
81% of patients (Table 2). In patients with a previous MACE,
the median CACS was significantly higher (1013, IQR 530–
1306, P = 0.03), with more patients being in a higher CACS
class (P < 0.001). The median CACS was 13 in patients with
severe hemophilia (IQR 0–251), 4 in those with moderate
hemophilia (IQR 0–42), and 0 in those with mild hemophilia
(IQR 0–99) (P = 0.57). No differences in CACS were seen
when hemophilia A and B patients were compared: the median
CACS was 8 in those with hemophilia A (IQR 0–123) and 0 in
those with hemophilia B (IQR 0–101) (P = 0.57). The per-
centage of patients with a higher CACS was positively
associated with an increasing SCORE risk, as shown in
Fig. 2A (P < 0.001). The patients with diabetes mellitus are
shown separately, as the SCORE risk calculation is not
validated for diabetic patients.
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IMT
IMTwasmeasured in 65 patients. Four patients cancelled their
appointment for unknown reasons. These four patients did not
have a previous MACE, and all had an evaluable CACS.
Carotid IMT results and age-dependent reference values are
shown in Fig. 1B. The mean carotid IMT in hemophilic
patients was 0.80 mm (95% CI 0.76–0.84 mm) (Table 2), and
did not differ from the reference values. The median carotid
IMT was significantly higher in patients with a previous
MACE than in patients without a previous MACE: 1.09 mm
(95% CI 0.94–1.25 mm) vs. 0.76 mm (95% CI 0.73–
0.79 mm) (P < 0.0010). For five patients, comparison with
the reference value was not possible, because they were aged
> 70 years. Eighteen of the 65 patients (28%) had an IMT
above the 80th percentile of the age-dependent reference values,
and were considered to be abnormal. The mean IMT was
0.74 mm in patients with severe hemophilia (95% CI 0.69–
0.80 mm), 0.77 mm in those with moderate hemophilia
(95% CI 0.64–0.94 mm), and 0.76 mm in those with mild
hemophilia (95% CI 0.72–0.81 mm) (P = 0.81). No differ-
ences in IMT were seen when hemophilia A and B patients
were compared: the mean IMT was 0.75 mm in hemophilia A
patients (95% CI 0.71–0.80 mm) and 0.76 mm in hemo-
philia B patients (95% CI 0.69–0.84 mm) (P = 0.78). There
was a clear relationship between the SCORE risk and IMT
(Fig. 2B). With ANOVA, differences in carotid IMT were
significant for the different risk groups (P < 0.001).
Discussion
This study evaluated the presence of atherosclerosis in patients
with hemophilia as measured by CACS and IMT. The extent
of atherosclerosis was in accordance with the normal age-
dependent reference values for both measures, and was
independent of hemophilia type or severity. Therefore, these
data do not confirm the alleged protection given by hemophilia
against atherosclerosis [13–15]. Moreover, hemophilic patients
with a previousMACEhad increased CACS and/or IMT. This
suggests similar development of atherosclerosis as in patients




a MACE (n = 60)
Patients with
a MACE
(n = 9) P-value
Patient characteristics
Median age in years (IQR) 52 (43–64) 51 (42–62) 69 (61–74) 0.03
Type of hemophilia, no. (%)
Hemophilia A 51 (74) 45 (75) 6 (67) 0.60
Hemophilia B 18 (26) 15 (25) 3 (33)
Severity, no. (%)
Severe 27 (39) 23 (38) 4 (44) 0.48
Moderate 8 (12) 7 (12) 1 (11)
Mild 34 (49) 30 (50) 4 (44)
HIV infection, no. 0 0 0 NA
Hepatitis C infection, no. (%) 41 (62) 37 (64) 4 (44) 0.45
Cardiovascular risk factors
Overweight, no. (%) 36 (53) 31 (53) 5 (56) 0.87
Positive family history of premature
cardiovascular events, no. (%)
13 (19) 9 (16) 4 (44) 0.06
Smoking, no. (%)
Current 21 (31) 19 (33) 2 (22) 0.80
Former 29 (43) 25 (43) 4 (45)
Never 17 (26) 14 (24) 3 (33)
Blood pressure
Median systolic blood pressure (mm Hg) (IQR) 130 (125–150) 130 (121–145) 160 (139–178) 0.007
Median diastolic blood pressure (mm Hg) (IQR) 80 (75–85) 80 (75–85) 80 (78–98) 0.12
Systolic hypertension, no. (%) 30 (44) 23 (38) 7 (78) 0.03
Diastolic hypertension, no. (%) 9 (13) 5 (8) 4 (44) 0.003
Use of antihypertensives, no. (%) 18 (27) 10 (17) 8 (89) < 0.001
Median total cholesterol (mmol L)1) (IQR) 4.9 (4.1–5.7) 4.9 (4.1–5.7) 4.6 (4.0–5.5) 0.80
Median triglycerides (mmol L)1) (IQR) 1.4 (1.0–1.9) 1.4 (0.9–2.0) 1.5 (1.1–2.2) 0.47
Median HDL cholesterol (mmol L)1) (IQR) 1.3 (1.1–1.5) 1.3 (1.1–1.5) 1.3 (1.0–1.5) 0.96
Median LDL cholesterol (mmol L)1) (IQR) 3.2 (2.6–4.0) 3.2 (2.6–4.0) 2.9 (2.6–3.9) 0.25
Use of cholesterol-lowering drugs, no. (%) 8 (12) 3 (5) 5 (56) < 0.001
Diabetes mellitus, no. (%) 7 (10%) 6 (10%) 1 (11%) 0.92
HIV, human immunodeficiency virus; IQR, interquartile range; MACE, major adverse cardiovascular event; NA, not applicable. All P-values
are for comparison between patients with and without a previous MACE. Chi-squared Fishers exact test for categorical data; Mann–Whitney test
for continuous variables.
26 M. Zwiers et al
 2011 International Society on Thrombosis and Haemostasis
without hemophilia, where increased CACS and/or IMT is
found in populations at high cardiovascular risk, such as after a
MACE [16–19]. Furthermore, in patients without a previous
MACE, CACS and IMT were positively correlated with the
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Fig. 1. Measures of subclinical atherosclerosis in patients with haemo-
philia. (A) Coronary artery calcification score (CACS) in patients with
hemophilia with and without a previous major adverse cardiovascular
event (MACE). Straight line: mean reference value of CACS. Dotted line:
mean + 1 standard deviation (SD) reference value of CACS. Fine dotted
line: mean + 2 SD reference value of CACS. (According to the Multi-
Ethnic Study of Atherosclerosis data.) (B) Intima–media thickness (IMT)
in patients with hemophilia with and without a previous major adverse
cardiovascular event (MACE). Straight line: 50th percentile of local ref-
erence values. Dotted lines: 20th and 80th percentiles of local reference
values. Fine dotted line: 5th and 95 percentiles of local reference values.








(n = 9) P value
CACS, median (IQR) 35 (0–110) 0 (0–67) 1013 (530–1306) 0.03
CACS in classes, no. (% of evaluable patients)
0–100 49 (74) 49 (81) 0 < 0.001
101–400 7 (11) 6 (10) 1 (17)
401–1000 6 (9) 4 (7) 2 (33)
> 1000 4 (6) 1 (2) 3 (50)
Carotid IMT (mm), geometric
mean (95% CI)
0.80 (0.76–0.84) 0.76 (0.73–0.79) 1.09 (0.95–1.26) 0.003
CI, confidence interval; IQR, interquartile range; MACE, major adverse cardiovascular event. CACS was available in 66 patients; in three patients
with a previous MACE, CACS was not assessed. All P-values are for comparison between patients with and without a previous MACE, corrected







































Fig. 2. Measures of subclinical atherosclerosis according to different car-
diovascular risk groups. Coronary artery calcification score (CACS)
classes (A) and intima–media thickness IMT (B) of the groups with dif-
ferent estimated risk according to the Systemic Coronary Risk Evaluation
risk classification: the group after a previous major adverse cardiovascular
event (MACE), and the group with type 2 diabetes mellitus (DM).
P < 0.001 for the differences in CACS class for the different risk groups
by the chi-squared test. P < 0.001 for the differences in carotid IMT for
the different risk groups by ANOVA.
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higher CACS and IMT. CACS and IMT were not related to
the severity of hemophilia. Together, these data suggest that the
development of atherosclerosis is dependent on the traditional
risk factors rather than being influenced by hypocoagulability.
It is important to note that CACS and IMT both quantify
only a part of the sequence of atherosclerotic changes in the
arterial wall that can eventually lead to thrombosis and a
clinical cardiovascular event. Therefore, this study does not
answer the question of whether hemophilic patients are, indeed,
relatively protected from cardiovascular events.
Our results are in line with two other studies that did not find
lower IMT in patients with hemophilia [11,12]. The difference
in findings as compared with three studies reporting lower IMT
may be explained by several factors. In the first study by Bilora,
a mixed group of patients with hemophilia and von Wille-
brands disease was studied, but the exact number of hemo-
philic patients and their specific characteristics were not
reported [13]. Furthermore, the prevalence of plaques and
degree of stenosis were studied rather than the IMT value itself,
the exact definition of plaquewas unclear, and it is questionable
whether the selected controls were really free from atheroscle-
rotic risk factors, as plaques were observed in 42 of the 77
controls. Similarly, in the secondBilora study, amixed group of
patients with hemophilia and von Willebrands disease was
studied [14]. Another important difference from our study
concerns the outcome measures, as they studied the aorta, the
femoral artery, and the popliteal artery, whereas we studied the
carotid arteries. Again, the definition of plaques was unclear,
the specific characteristics of the hemophilic patients were not
given, and the authors did not report on whether or not the
presence of atherosclerotic plaques was related to the athero-
sclerotic risk factors. In the third Bilora study, the carotid
arteries, the aorta and the brachial and femoral arteries were
studied. However, there was an inconsistent description of their
study group; they were referred to as patients with hemophilia
in some places in the paper, and as carriers of hemophilia in
other places [15]. Nevertheless, we cannot give a clear expla-
nation for their different IMT findings. It is remarkable that
they found higher IMT in the common carotid artery than at
the site of the carotid bulb in the hemophilic patients. In
contrast, within the control group, the absolute mean IMTs of
the common carotid artery and the carotid bulb were the same.
In our study, we found a higher IMT in the carotid bulb than in
the common carotid artery in the hemophilic patients (data not
shown), as is usually reported in the literature. Thus, a
difference in scanning technique could contribute to the
discrepancies.
Our study has some limitations. First, the percentage of non-
responders was 49%. In the group of non-responders, patients
without complications (including a previous MACE), who
rarely visit the outpatient clinic, were overrepresented. This
could have led to selection bias, although there was no
difference in the severity or type of hemophilia between
responders and non-responders. Second, the number of
included patients (n = 69) did not allow us to perform
subgroup analyses with sufficient power.
A strong aspect of our study is the use of CACS as a
measure for atherosclerosis. Not only has CACS never been
studied before in hemophilic patients, but the technique for
measuring CACS is standardized worldwide, in contrast to
the IMT technique, the absence of consensus for which makes
it difficult to compare the results of different study groups.
For example, there are large differences in ultrasound
transducer position and angle, which artery segments are
measured (common carotid, internal carotid, and/or carotid
bulb), in the use of the far wall or near wall, in whether the
mean or the maximum IMT is used, and in whether or not
the results of different segments are averaged. As a conse-
quence, each IMT study needs its own local reference values
or a separate control group. For CACS, the MESA values are
the worldwide reference values derived from a healthy cohort,
from which we used the data of 2619 Caucasian control
subjects [26].
In conclusion, patients with hemophilia are not protected
against the development of atherosclerosis. Their extent of
atherosclerosis is related to the calculated risk based on the
traditional cardiovascular risk factors. These findings sug-
gest that they should be monitored for traditional cardio-
vascular risk factors and receive counselling and preventive
measures, like any other person at risk for cardiovascular
events.
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